Carissa Karg

Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody

Allan C. deCamp, J. Mascola, P. Gilbert, 2021, Journal of acquired immune deficiency syndromes.

Recommendations for the follow-up of study participants with breakthrough HIV infections during HIV/AIDS biomedical prevention studies

S. Riddler, A. Tsibris, R. Landovitz, 2013, AIDS.

HIV vaccine-induced sero-reactivity: a challenge for trial participants, researchers, and physicians.

H. Zinszner, R. Coombs, P. Fast, 2015, Vaccine.

A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline Findings

J. Mascola, J. Ledgerwood, L. Corey, 2021, Journal of acquired immune deficiency syndromes.

Post-COVID symptom profiles and duration in a global convalescent COVID-19 observational cohort: Correlations with demographics, medical history, acute COVID-19 severity and global region

P. Goepfert, S. Karuna, Maurine D. Miner, 2023, Journal of global health.

Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized Trials

J. Mascola, J. Ledgerwood, L. Corey, 2021, Journal of acquired immune deficiency syndromes.